DexCom Inc. (D1EX34) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of DexCom Inc. BRL 8.68, price BRL 8.98, upside -3.3%, quality 81 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch DexCom Inc. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 29, 2026.
How to read this chart
60‑month range R$5.75 – R$18.31 · fair‑value band R$5.42 – R$13.24 · the R$8.98 price screens above the R$8.68 fair value. Dashed = 300-day average. As of Sep 29, 2026.
Follow DexCom in your weekly email
Every Wednesday you see whether DexCom is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally.
Show more
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Stock analysis
DexCom Inc. (D1EX34) currently trades at R$8.98, while our model-based Fair Value estimate is R$8.68, so the stock looks roughly fairly valued today (gap 3.5%).
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of R$6.50 per share, and 1 of the 24 models we run sit above the R$8.98 price.
Bear case: the Economic Profit group reads lowest at R$2.16, and 23 of the 24 models stay below the price. Evidence for this calculation is medium.
Scenario range: R$5.42 (bear) to R$13.24 (bull), the price of R$8.98 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 81/100 (high quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
DexCom Inc. reported revenue of $4.7B in FY2025 versus $2.4B in FY2021, a compound +17.5%/yr. Reported net income was $836M in FY2025, compounding +40.1%/yr from FY2021.
Key figures
Market cap R$153B (≈ $29.3B) · P/E ratio 37.4 · P/S ratio 6.71 · EPS (TTM) R$0.2400 · Net margin 17.9% · Return on equity 35.6% · Return on assets (EBIT) 9.2% · Operating margin 21.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).
What moves the price
The share trades about 5% below its 52-week high and 56% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −3%, D1EX34 screens richer than that median.
Fair Value models
Bear R$5.42Fair Value R$8.68Bull R$13.24
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (R$0.1815 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+15.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.3%
Start year 2020 (pandemic)
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
+29.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year+29.2%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.16% → 20%
2025 sits 55% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
News mood ⓘNews mood, the average tone of recent news (99 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Positive
Recent news coverage is more positive than average.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 351 stocks
Beats the industry median on 8/10 measures
Overall it ranks above its industry peers.
Valuation
Quality Score81 · Top 25%
Fair Value upside+10.6% · Above median
Profitability
Return on equity (TTM)35.6% · Top 25%
Return on assets9.7% · Top 25%
Net margin (TTM)19.3% · Top 25%
Operating margin (TTM)21.4% · Top 25%
Growth and dividend
Revenue growth15.0% · Above median
Balance sheet
Debt / equity0.45× · Highest 25%
Valuation Multiplesvs Medical Devices median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "DexCom Inc. Fair Value". https://www.fairvalue-calculator.com/stock/D1EX34
Frequently asked questions
Is DexCom Inc. (D1EX34) overvalued or undervalued?
As of Sep 29, 2026, our model estimates a fair value of R$8.68 versus a price of R$8.98, about −3% upside (fairly valued).
What is the fair value of D1EX34?
Our model-based fair value for DexCom Inc. is R$8.68 (as of Sep 29, 2026), built from audited fundamentals. The current price: R$8.98.
What is the quality score of D1EX34?
DexCom Inc. has a Quality Score of 81/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for DexCom Inc. (D1EX34)?
Our model-based price target is the fair value of R$8.68 (as of Sep 29, 2026) from 24 valuation models. Cautious scenario R$5.42, optimistic scenario R$13.24. It is a calculation from audited fundamentals, not an analyst target.
What is the DexCom Inc. stock forecast for 2026?
Our models put fair value at R$8.68, about −3% upside versus a price of R$8.98 (fairly valued). Cautious scenario R$5.42, optimistic scenario R$13.24. The calculation is refreshed regularly with new filings.
What is the revenue of DexCom Inc. (D1EX34)?
DexCom Inc. reported trailing-twelve-month revenue of about $4.8B (latest available figure, as of Sep 29, 2026).
What is the intrinsic value of DexCom Inc. (D1EX34)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For DexCom Inc. it is R$8.68 per share (as of Sep 29, 2026), against a price of R$8.98. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is DexCom Inc. stock overvalued or undervalued in 2026?
As of Sep 29, 2026, D1EX34 trades above its calculated fair value: price R$8.98, fair value R$8.68, a gap of about −3% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of D1EX34?
No. The price is what the market pays today (R$8.98); the fair value is what the company's own numbers justify (R$8.68). For DexCom Inc. the two are R$0.3000 per share apart. That gap is exactly why we show both numbers side by side.
How much is DexCom Inc. worth?
The market values DexCom Inc. at about R$153B (market capitalisation, as of Sep 29, 2026). Per share that is R$8.98; our models calculate a fair value of R$8.68 per share.
What do the bullish and bearish scenarios say about D1EX34?
Our models span a range for DexCom Inc.: cautious scenario R$5.42, base R$8.68, optimistic R$13.24 per share (as of Sep 29, 2026, price R$8.98). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of D1EX34?
DexCom Inc. trades at a price-to-earnings ratio of 37.4 (as of Sep 29, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of R$8.68 is built from several models across several years. Other multiples: PEG 1.4.
What is the PEG ratio of D1EX34?
The PEG ratio of DexCom Inc. is 1.43 (P/E divided by earnings growth, as of Sep 29, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of DexCom Inc. (D1EX34)?
Balance-sheet figures for DexCom Inc. (as of Sep 29, 2026): return on equity 35.6%, debt of 0.45 per unit of equity. They feed the Quality Score of 81/100, which measures business quality independently of the share price.
How far is D1EX34 from its 52-week high?
DexCom Inc. trades at R$8.98, about 5% below its 52-week high of R$9.47 and 56% above the low of R$5.75 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of R$8.68 is for.
Which stocks are comparable to DexCom Inc.?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is DexCom Inc. stock attractive at the current price?
The data as of Sep 29, 2026: price R$8.98, calculated fair value R$8.68 (−3%), Quality Score 81/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of D1EX34 calculated?
We run DexCom Inc. through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of R$8.68, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. DexCom Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of DexCom Inc. (D1EX34)?
The closing price on Oct 2, 2026 was R$8.98. Our model-based fair value is R$8.68, about −3% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with DexCom Inc. right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (R$5.42 to R$13.24) leaves room in how you read the outcome.
Key figures of DexCom Inc.
How large is the market capitalisation of DexCom Inc. (D1EX34)?
The market capitalisation of DexCom Inc. is R$153B (≈ $29.3B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of DexCom Inc. (D1EX34)?
The price-to-sales ratio of DexCom Inc. is 6.71 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of DexCom Inc. (D1EX34)?
Earnings per share at DexCom Inc. are R$0.2400 (price ÷ EPS = P/E 37.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of DexCom Inc. (D1EX34)?
The net margin of DexCom Inc. is 17.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of DexCom Inc. (D1EX34)?
The return on equity (ROE) of DexCom Inc. is 35.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of DexCom Inc. (D1EX34)?
On an EBIT basis the return on assets of DexCom Inc. is 9.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of DexCom Inc. (D1EX34)?
The operating margin of DexCom Inc. is 21.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at DexCom Inc. (D1EX34)?
Revenue at DexCom Inc. is growing +15.0% versus a year earlier (3y avg +17.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at DexCom Inc. (D1EX34)?
Earnings per share at DexCom Inc. are growing +92.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does DexCom Inc. (D1EX34) generate?
The free cash flow of DexCom Inc. is $1.1B (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does DexCom Inc. (D1EX34) carry?
The net debt of DexCom Inc. is $323M (fiscal year 2025, ≈ 0.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch DexCom Inc. in the live analysis
One click puts DexCom Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
